Auria Biopankki
Auria Biopankki is a Finnish hospital biobank under Varha that collects, stores, and distributes over one million human biological samples and clinical data to academic researchers and pharmaceutical and diagnostic companies across three regional health districts.
- Company typePrivate
- Founded2012
- HeadquartersTurku, Finland
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Auria Biopankki does
Auria Biopankki is a Finnish hospital biobank, founded in 2012 and licensed in 2014, operating as a regional service area within Tyks Laboratoriot under the Varsinais-Suomen hyvinvointialue (Varha) public welfare authority. It collects, stores, and distributes human biological samples — including blood, tissue, and derived products such as the OvaCure ovarian cancer organoid collection — and links them to associated clinical data across three Finnish hospital districts (Varsinais-Suomi, Satakunta, and Vaasa). Following the 2024 merger with Terveystalo's biobank operations, it holds over one million samples, making it Finland's largest biobank and the first in Finland and the Nordics to achieve FINAS accreditation (B001) under SFS-EN ISO 20387:2020.
The company serves three customer segments: academic and clinical researchers (primarily via the University of Turku), pharmaceutical and diagnostic companies, and citizens/patients who consent to sample storage during routine clinical procedures. Researchers access samples through the Fingenious® digital platform and a scientific steering group approval process, while citizens provide consent through digital channels (the Varha and Sata mobile applications) or paper forms during healthcare visits. The technology stack centres on biobank infrastructure operating under the strictest international biobanking standard, with no disclosed AI/ML capabilities.
Auria Biopankki's business model combines public funding through the Finnish regional welfare authority with commercial revenue from professional services — specifically sample and data provision fees, and collaborative research partnerships such as the Aqsens Health bladder-cancer biosensor project. Pricing is not publicly disclosed and access is gated by application, suggesting negotiated, project-based contracts with academic and industry clients rather than high-volume transactional sales. The entity is government-owned, not venture-backed, and is governed as public healthcare infrastructure.
Auria Biopankki firmographics
Firmographics- Name
- Auria Biopankki
- Legal name
- Auria Biopankki
- Website
- https://auriabiopankki.fi
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Auria Biopankki is a Finnish hospital biobank under Varha that collects, stores, and distributes over one million human biological samples and clinical data to academic researchers and pharmaceutical and diagnostic companies across three regional health districts.
- Ownership category
- akta.pro rank
Auria Biopankki industry classification
Industry- Product category
- Biobanking Services
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Biobank & Biospecimen Management LIMS (HLACAMAG)
- akta.pro secondary industries
- Sample / Biorepository & Biobank Informatics (Chain-of-Custody) (HLAGAJAH), Specimen Referral, Transport & Chain-of-Custody Coordination Networks (HLAJAIAO), Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI)
Keywords
Where Auria Biopankki is headquartered
LocationHeadquarters
- HQ city
- Turku
- HQ country
- Finland
- HQ region
- Europe
Offices3 records
Markets served
Auria Biopankki business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Others
Revenue model
- Sample and data provision services: Auria Biopankki provides high-quality human-derived samples and associated clinical data to biomedical researchers, including academic institutions, pharmaceutical companies, and diagnostic companies. Revenue is generated through service fees for sample processing, preparation, and delivery under approved research protocols.
- Research collaboration services: The biobank engages in collaborative research partnerships with healthcare providers and technology companies, such as the joint bladder cancer detection research with Aqsens Health Oy.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels7 records
Auria Biopankki product offering
Product offeringCore offering
Auria Biopankki collects, stores, and distributes human biological samples (blood, tissue, and other specimens) along with associated clinical data to academic researchers and pharmaceutical/diagnostic companies. Following its 2024 merger with Terveystalo's biobank operations, it holds over one million samples across three Finnish hospital districts. Access is governed by scientific steering group approval through the Fingenious® platform and operates under FINAS accreditation (SFS-EN ISO 20387:2020).
Product overview
Auria Biopankki is Finland's oldest hospital biobank, operating as part of Tyks Laboratory Services in connection with the University of Turku. The core offering is a biobank containing over one million human samples used for biomedical research. The product portfolio includes the main Auria Biopankki service for storing and distributing samples to researchers, the OvaCure Collection for ovarian cancer organoid cultures, the Fingenious® platform for researchers to request samples, mobile applications (Varha-sovellus and Sata-sovellus) for citizens to provide digital consent, an interactive consent map (Suostumuskartta), and sample collection services at TUAS Lab.
Differentiator
Problem solved
Functional benefit
Products and services
- Auria Biopankki Biobanking Service Core biobanking service that collects, stores, and distributes human biological samples (blood, tissue, and other specimens) and associated clinical data for biomedical research. Serving academic researchers at universities and university hospitals, plus pharmaceutical and diagnostic companies, with sample access governed by scientific steering group approval.
- OvaCure Collection A specialized collection of stable and well-characterised organoid cultures derived from patient-derived high-grade serous ovarian tumour samples, made available to researchers studying ovarian cancer.
- Fingenious® Platform Digital platform used by researchers to discover available sample collections and submit sample requests to Auria Biopankki for scientific research purposes.
Quantifiable outcome
- Over 1 million samples available for research following the merger with Terveystalo biobank
Companies that use Auria Biopankki
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Auria Biopankki technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature2 records
Auria Biopankki partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered flagship, core and minor.
- Terveystalo Biopankki (merged into Auria)flagshipTerveystalo's biobank operations transferred to Varsinais-Suomen hyvinvointialue (Varha) and merged into Auria Biopankki. This merger created Finland's largest biobank with over one million samples. Terveystalo's biobank samples and donor registry were incorporated into Auria's operations.
- Turku University (Turun yliopisto)coreOne of the founding organisations of Auria Biopankki. Provides research expertise, academic infrastructure, and researchers who access biobank samples. The biobank is located in the University of Turku's hospital complex.
- Tyks Laboratoriot (Tyks Laboratory)coreAuria Biopankki is one of five service areas within the Tyks Laboratory results group. The biobank operates within the Tyks hospital ecosystem, integrating sample collection with clinical care.
- Varsinais-Suomen hyvinvointialue (Varha)coreThe wellbeing services county that owns Auria Biopankki following the 2024 administrative restructuring. Varha provides the administrative and healthcare infrastructure within which the biobank operates. Citizens can give biobank consent via the Varha app.
- Aqsens Health OycoreAqsens Health Oy, Tyks, and Auria Biopankki are collaborating on a research project to validate the use of Aqsens-developed phage-biosensors for detecting and classifying bladder cancer from urine samples. The study focuses on monitoring bladder cancer progression and detecting disease recurrence non-invasively.
- Turku University of Applied Sciences (TUAS)minorTUAS operates the TUAS Lab (Medisiina D, Turku) where citizens can give dedicated biobank blood samples by appointment. Bioanalyist students perform sample collection under supervision. The service is provided free of charge to sample donors.
- Fingenious®coreFingenious® is a digital platform used by researchers to discover and request access to biobank samples. It is referenced as the primary interface for researchers seeking sample access from Auria Biopankki.
- OvaCureminorOvaCure is a collection of stable, well-characterised organoid cultures derived from patient-derived high-grade serous ovarian tumour samples held within Auria Biopankki. The collection was published in a scientific journal (ScienceDirect).
- iCan National Cancer ProgrammeminorThe iCan national programme allocated 2.5 million euros in funding to regional cancer centres for biobank projects. Auria Biopankki is involved in this programme alongside other Finnish biobanks and cancer centres.
- Satakunnan hyvinvointialue (Satakunnan HVA)minorOne of the original founding hospital districts. Citizens of Satakunnan can give biobank consent via the Sata app. Staff presence maintained in Pori.
- Vaasan keskussairaala (Vaasa Central Hospital)minorOne of the original founding hospital districts. The biobank operates in association with Vaasan keskussairaala for sample collection in the Vaasa region.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
Auria Biopankki competitors and assessment
Company assessmentBroad incumbents
- deCODE genetics (Amgen): Population-scale human genetics and biobanking company. Comparable in providing well-characterised human samples and health data to pharmaceutical and academic researchers, but operates commercially at a much larger scale with proprietary genomic profiling capabilities.
- BioIVT: Global supplier of human biological specimens and disease-state samples to pharma and diagnostic researchers. Comparable in offering high-quality human samples for drug development and diagnostic validation, but operates as a commercial sample vendor rather than a hospital biobank.
- Brooks Life Sciences / BioStorage Technologies: Specialist in sample management, biobanking services, and cold-chain logistics for life science research. Comparable in offering biorepository and chain-of-custody services, though focuses more on sample storage logistics than on hospital-based clinical collection.
- BBMRI-ERIC: European biobanking research infrastructure consortium that federates national biobanks, including Auria-adjacent Finnish nodes. Comparable in aggregating biobank samples for cross-border research, but operates as a federation rather than a sample provider directly.
- UK Biobank: Large-scale population biobank with deep clinical phenotyping and established pharma research partnerships. Comparable in offering human samples and health data for biomedical research, but operates at national-population scale and is globally recognised, whereas Auria is regional.
Direct peers
- Biobank Graz (Medical University of Graz): University-hospital biobank operating under ISO-accredited quality standards, providing human samples for biomedical research. Closely comparable in hospital-embedded operating model, ISO accreditation status, and academic-pharma customer mix.
- Helsinki Biobank (HUS): Finland's largest hospital biobank by catchment prior to Auria's Terveystalo merger, operating within Helsinki University Hospital (HUS). Closely comparable in Finnish regulatory framework, hospital integration, and competing for the same pharma and academic sample requests.
- Karolinska Institutet Biobank: Swedish hospital biobank supporting biomedical research with clinically annotated human samples. Directly comparable in hospital-anchored Nordic operating model, regulatory oversight, and customer base of academic and pharma researchers.
Emerging players
- Crown Bioscience (JSR Life Sciences): Translational research services company offering patient-derived organoid models, xenograft platforms, and biobank-derived samples for oncology research. Comparable via the OvaCure Collection's organoid angle, though operates as a global commercial CRO rather than a public hospital biobank.
Regional players
- Finnish Biobanks (FinnGen / BBMRI.fi network): National network of Finnish hospital biobanks, including Auria's peers such as Helsinki Biobank, THL Biobank, and Terveystalo's prior operations. Directly comparable in operating model (hospital-anchored, ISO-aligned, public-sector ownership) and in competing for the same Finnish patient populations and pharma research contracts.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Auria Biopankki social profiles
Digital presenceAuria Biopankki compliance and trust
Trust signalCompliance1 record
Auria Biopankki financial estimates
Financial estimateRevenue estimate
Valuation estimate
Auria Biopankki leadership team
Management profileNumber of profiles
Profiles10 records
Auria Biopankki funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Auria Biopankki M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Auria Biopankki
What does Auria Biopankki do?
Auria Biopankki collects, stores, and distributes human biological samples (blood, tissue, and other specimens) along with associated clinical data to academic researchers and pharmaceutical/diagnostic companies. Following its 2024 merger with Terveystalo's biobank operations, it holds over one million samples across three Finnish hospital districts. Access is governed by scientific steering group approval through the Fingenious® platform and operates under FINAS accreditation (SFS-EN ISO 20387:2020).
Is Auria Biopankki a public or private company?
Auria Biopankki is a private company. It is classified as state government owned and is currently operating.
When was Auria Biopankki founded?
Auria Biopankki was founded in 2012. It employs 11 to 50 people.
Where is Auria Biopankki based?
Auria Biopankki is headquartered in Turku, Finland, in the Europe region.
How does Auria Biopankki make money?
Two revenue lines are on record. Sample and data provision services are the primary driver. The others are research collaboration services.
Who are Auria Biopankki's main competitors?
Broad incumbents on record are deCODE genetics (Amgen), BioIVT, Brooks Life Sciences / BioStorage Technologies, BBMRI-ERIC and UK Biobank. Direct peers are Biobank Graz (Medical University of Graz), Helsinki Biobank (HUS) and Karolinska Institutet Biobank. Crown Bioscience (JSR Life Sciences) is listed as an emerging player. Finnish Biobanks (FinnGen / BBMRI.fi network) is listed as a regional player.
Does Auria Biopankki have an API?
No public API is recorded for Auria Biopankki.
What industry is Auria Biopankki in?
Auria Biopankki's product category is Biobanking Services. Its primary akta.pro industry code is HLACAMAG, Biobank & Biospecimen Management LIMS, with a secondary code of HLAGAJAH, Sample / Biorepository & Biobank Informatics (Chain-of-Custody). Its NAICS code is 621511 and its SIC code is 8071.